Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
AssigneeChiesi Farmaceutici S.p.A.
InventorsFrancesca BUTTINI, Giada VARACCA, Romina OSELLO
Life of this patent
Estimating the term…
Abstract
The present invention relates to a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition loaded in a capsule, the pharmaceutical composition comprising micronized particles of the compound of formula (I) and a carrier. The present invention also relates to a pharmaceutical composition for use for the treatment of a respiratory disease and to a method for the treatment of a respiratory disease.
Claims9
A drug product, comprising a single-dose dry powder inhalation device, comprising an inhaler body (2) defining a recess (3) for a capsule (4), wherein the capsule (4) holds herein a pharmaceutical composition to be inhaled, a nosepiece or mouthpiece (5) communicating with the recess (3), at least one rupturing element (7) coupled to the inhaler body (2) and configured for rupturing the capsule (4) to allow an outside airflow to be mixed with the pharmaceutical composition of the capsule (4) and inhaled through the nosepiece or the mouthpiece (5), and
- a pharmaceutical composition filled in a capsule, the pharmaceutical composition comprising micronized particles having a size of from 0.1 to 15 microns of a compound of formula (I)
- and carrier particles,
- wherein the inspiratory flow rate of said inhaler is from 30 l/min to 65 l/min at 4 kPa of pressure drop, and
- wherein the unitary nominal dose of the compound of formula (I) is from 450 to 600 μg.
A method for the treatment of a respiratory disease, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising micronized particles having a size of from 0.1 to 15 microns of a compound of formula (I)
- and carrier particles,
- wherein said composition is administered using a single-dose dry powder inhalation device whose inspiratory flow rate is from 30 l/min to 65 l/min, and
- wherein the unitary dose of the compound of formula (I) is from 450 to 600 μg.
Dependencies are inferred from the claim text.